EP0716093B1 - Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel - Google Patents

Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel Download PDF

Info

Publication number
EP0716093B1
EP0716093B1 EP95402744A EP95402744A EP0716093B1 EP 0716093 B1 EP0716093 B1 EP 0716093B1 EP 95402744 A EP95402744 A EP 95402744A EP 95402744 A EP95402744 A EP 95402744A EP 0716093 B1 EP0716093 B1 EP 0716093B1
Authority
EP
European Patent Office
Prior art keywords
formula
radical
compounds
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95402744A
Other languages
English (en)
French (fr)
Other versions
EP0716093A1 (de
Inventor
Constantin Agouridas
Jean-François Chantot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Hoechst Marion Roussel
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel, Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel
Publication of EP0716093A1 publication Critical patent/EP0716093A1/de
Application granted granted Critical
Publication of EP0716093B1 publication Critical patent/EP0716093B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to new derivatives of erythromycin, their preparation process and their application as drugs.
  • salts of the present derivatives with mineral or organic acids mention may be made of salts formed with acetic, propionic, trifluoroacetic acids, maleic, tartaric, methanesulfonic, benzenesulfonic, p-toluenesulfonic, hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric and especially stearic, ethylsuccinic and laurylsulfonic acids.
  • the acyl radical is preferably an acetyl radical, propionyl, butyryl, isobutyryl, n-valeryl, isovaleryl, tert-valeryl, pivalyl or phenylmethoxycarbonyl.
  • the heterocyclic radical has one or more heteroatoms preferably chosen from oxygen, sulfur and nitrogen.
  • heterocyclic radical When the heterocyclic radical is substituted, it preferably by one or more chosen substituents among the halogen atoms, hydroxy, alkyl radicals, alkyloxy, aryl, aryloxy containing up to 18 atoms of carbon.
  • the subject of the invention is particularly the compounds of formula (I) in which R 3 is an N (CH 2 ) q R 4 , q and R 4 radical retaining their previous meaning and in particular in which q represents the value 3.
  • a more particular subject of the invention is the compounds of formula (I) in which the heterocycle radical R 4 contains at least one nitrogen atom, in particular those in which the heterocyclic radical is an imidazolyl, pyridinyl, thiazolyl, quinolinyl or azabenzimidazolyl radical , optionally substituted and more especially a 4-phenyl 1H-imidazolyl or 4-quinolinyl radical.
  • the invention particularly relates to compounds of formula (I) the preparation of which is given below in the experimental part and especially the products of examples 1, 2, 3 and 4.
  • the subject of the invention is also a process for preparing the compounds of formula (I), characterized in that a compound of formula (II) is subjected: in which R 2 retains its previous meaning, Bn represents a benzyloxycarbonyl radical and Ac an acyl radical as defined above, to the action of a compound of formula (III): R 3 NH 2 in which R 3 retains its previous meaning to obtain the compounds of formula (IV): which is subjected if desired to the action of a cleavage agent of the ester function at 2 'to obtain the compound of formula (I) in which R 1 is an OH radical, then submits if desired the compound thus obtained the action of a reducing agent to effect the cleavage of the benzyloxy carbonyl group into 4 "and to obtain the product of formula (I) in which R represents an OH radical and then, if desired, subject the compound of formula (I) the action of an acid to form the corresponding salt.
  • the amines of formula (III) are known in a way general and can be prepared according to the methods described in J. Med. Chem. (1982) vol. 25, p. 947 and following or yet Tetrahedron Letters vol. 32 n ° 14, p. 1699, 1702 (1991).
  • the cleavage of the acetate in 2 ' is carried out using the methanol or aqueous hydrochloric acid.
  • the cleavage of the benzyloxycarbonyl group into 4 is carried out by reduction, for example by means of hydrogen in presence of a palladium catalyst.
  • Salification is carried out using acid according to the conventional processes.
  • the compounds of formula (I) in which R 3 is a radical -N (CH 2 ) q R 4 can be prepared by the action of hydrazine hydrate on the product of formula (II) to obtain the compound of formula ( P), that is to say a product of formula (I), in which R 3 represents NH 2 , which is subjected to the action of an aldehyde R 4 (CH 2 ) q-1 CHO, to obtain the corresponding compound of formula (I).
  • the compound of formula (P) is a product of the invention as a new chemical.
  • the compounds of the invention can therefore be used as drugs in the treatment of germ infections sensitive and in particular, in that of staphylococcal diseases, such as staphylococcal septicemia, staphylococcal disease facial or skin malignancies, pyoderma, sores septic or suppurative, boils, carbuncles, phlegmons, erysipelas and acne, staphylococcal diseases such as angina primitive or post-flu acute, bronchopneumonia, pulmonary suppuration, streptococcal disease such as acute angina, ear infections, sinusitis, scarlet fever, pneumococcal diseases such as pneumonia, bronchitis; the brucellosis, diphtheria, gonococcal disease.
  • staphylococcal diseases such as staphylococcal septicemia, staphylococcal disease facial or skin malignancies, pyoderma, sores septic or suppurative, boils, carbuncles
  • the products of the present invention are also active against infections caused by germs like Haemophilus influenzae, Moraxella catarrhalis, Rickettsies, Mycoplasma pneumoniae, Chlamydia, Legionella, Ureaplasma, Toxoplasma or germs of the genus Mycobacterium.
  • the present invention therefore also has for its object, as medicines and, in particular antibiotic medicines, the products of formula (I) as defined above, as well as their addition salts with mineral acids or pharmaceutically acceptable organic.
  • the subject of the invention is more particularly, by way of drugs, including antibiotic drugs, the preferred products of formula (I) defined above in know the products of examples 1, 2, 3 and 4, as well as their pharmaceutically acceptable salts.
  • the invention also relates to the compositions pharmaceuticals containing as active ingredient at least one of the drugs defined above.
  • compositions can be administered by the buccal, rectal, parenteral or locally applied topically on the skin and mucous membranes, but the way preferred administration route is the oral route.
  • compositions pharmaceuticals can be solid or liquid and present in pharmaceutical forms commonly used in medicine human, such as tablets, simple or sugar-coated tablets, capsules, granules, suppositories, injections, ointments, creams, gels; they are prepared according to the usual methods.
  • the or the active ingredients can be incorporated therein excipients usually used in these compositions pharmaceuticals, such as talc, gum arabic, lactose, starch, magnesium stearate, butter cocoa, aqueous vehicles or not, original fatty substances animal or vegetable, paraffinic derivatives, glycols, the various wetting, dispersing or emulsifying agents, conservatives.
  • compositions can also be presented under form of a powder intended to be dissolved extemporaneously in a suitable vehicle, for example sterile water nonpyrogenic.
  • the dose administered is variable depending on the condition treated, subject, route of administration and product considered. It can be, for example, understood between 50 mg and 300 mg per day orally, in adults for the product of Example 4 or 2.
  • stage b) The product obtained in stage b) is dissolved in 100 ml of methanol. Hydrogenolysis is carried out in the presence of 600 mg of 10% palladium on activated carbon. It is filtered, rinsed with methanol and with methylene chloride and then the filtrate is concentrated to dryness. 2.52 g of a product are obtained which is purified by eluting with an isopropyl ether-methanol-triethylamine mixture (80-10-10). 941.8 mg of a product are obtained, which product is chromatographed again, eluting with an isopropyl ether-methanol-triethylamine mixture (80-10-10).
  • rf 0.1 (isopropyl ether-methanol-triethylamine 80-10-10).
  • EXAMPLE 3 6-O-methyl 12,11- (oxycarbonyl (2- (3- (3H-imidazo (4,5-b) -pyridin-3-yl) propyl) hydrazono)) erythromycin.
  • rf 0.2 (isopropyl ether-methanol-triethylamine 80-10-10).
  • EXAMPLE 4 6-O-methyl 12,11- (oxycarbonyl (2- (3- (2-phenyl 4 - thiazolyl) propyl) hydrazono)) erythromycin.
  • the growth inhibition is assessed by transillumination, which makes it possible to determine the minimum inhibitory concentrations (MIC) expressed in micrograms / cm 3 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (13)

  1. Verbindungen der Formel (I)
    Figure 00180001
    worin
    R und R1 einen Hydroxylrest oder einen O-Acylrest mit 2 bis 20 Kohlenstoffatomen bedeuten,
    R2 für ein Wasserstoffatom oder einen Methylrest steht,
    R3 für einen Rest -N-(CH2)qR4 steht, worin q eine ganze Zahl von 0 bis 6 bedeutet, R4 einen gegebenenfalls substituierten, mono- oder polycyclischen, heterocyclischen Rest darstellt, sowie deren Additionssalze mit Säuren.
  2. Verbindungen der Formel (I) gemäß Anspruch 1, worin R und R1 einen Hydroxylrest bedeuten.
  3. Verbindungen der Formel (I) gemäß Anspruch 1 oder 2, worin R2 einen Methylrest bedeutet.
  4. Verbindungen der Formel (I) gemäß Anspruch 3, worin q den Wert 3 besitzt.
  5. Verbindungen der Formel (I) gemäß einem der Ansprüche 1 bis 4, worin der heterocyclische Rest R4 zumindest ein Stickstoffatom umfaßt.
  6. Verbindungen der Formel (I) gemäß Anspruch 5, worin der heterocyclische Rest unter den Imidazolyl-, Pyridinyl-, Thiazolyl-, Chinolyl- und Azabenzimidazolyl-Resten, welche gegebenenfalls substituiert sind, ausgewählt sind.
  7. Verbindungen der Formel (I) gemäß Anspruch 9, worin R4 einen 4-Phenyl-1H-imidazolyl- oder 4-Chinolylrest bedeutet.
  8. Verbindung der Formel (I) mit der folgenden Bezeichnung:
    11,12-Didesoxy-6-O-methyl-12,11-(oxycarbonyl-(2-(3-(4-chinolyl)-propyl)-hydrazono))-erythromycin.
  9. Verfahren zur Herstellung der Verbindungen der Formel (I) gemäß einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, daß man eine Verbindung der Formel (II)
    Figure 00190001
    worin R2 die vorstehende Bedeutung besitzt, Bn einen Benzyloxycarbonylrest bedeutet und Ac für einen Acylrest steht, wie in Anspruch 1 definiert, der Einwirkung einer Verbindung der Formel (III) R3NH2 worin R3 die vorstehende Bedeutung besitzt, unterzieht, um zu der Verbindung der Formel (IV)
    Figure 00200001
    zu gelangen, welche man gewünschtenfalls der Einwirkung eines Mittels zur Abspaltung der Esterfunktion in 2'-Stellung unterzieht, um zu der Verbindung der Formel (I) zu gelangen, worin R1 ein Rest OH ist, wonach man gewünschtenfalls die so erhaltene Verbindung der Einwirkung eines Reduktionsmittels unterzieht, um die Spaltung der Benzyloxycarbonylgruppe in 4"-Stellung, das Hydroxyl der Gruppe OBn, zu bewirken und das Produkt der Formel (I) zu erhalten, worin R einen Rest OH bedeutet, wonach man gewünschtenfalls die Verbindung der Formel (I) der Einwirkung einer Säure unterzieht, um hieraus das entsprechende Salz zu bilden.
  10. Als neues chemisches Produkt das 11,12-Didesoxy-6-O-methyl-12,11-(oxycarbonyl)-(hydrazono)-erythromycin.
  11. Als Arzneimittel die Verbindungen der Formel (I) gemäß Anspruch 1.
  12. Als Arzneimittel die Verbindung der Formel (I) gemäß Anspruch 8.
  13. Pharmazeutische Zusammensetzungen, enthaltend als Wirkstoff zumindest ein Arzneimittel, wie in Anspruch 11 oder 12 definiert.
EP95402744A 1994-12-09 1995-12-06 Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel Expired - Lifetime EP0716093B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9414807 1994-12-09
FR9414807A FR2727969B1 (fr) 1994-12-09 1994-12-09 Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Publications (2)

Publication Number Publication Date
EP0716093A1 EP0716093A1 (de) 1996-06-12
EP0716093B1 true EP0716093B1 (de) 1998-10-21

Family

ID=9469625

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95402744A Expired - Lifetime EP0716093B1 (de) 1994-12-09 1995-12-06 Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel

Country Status (14)

Country Link
US (1) US5786339A (de)
EP (1) EP0716093B1 (de)
JP (1) JP4083824B2 (de)
KR (1) KR100371473B1 (de)
CN (1) CN1067077C (de)
AT (1) ATE172467T1 (de)
AU (1) AU697876B2 (de)
CA (1) CA2164798C (de)
DE (1) DE69505487T2 (de)
DK (1) DK0716093T3 (de)
ES (1) ES2123934T3 (de)
FR (1) FR2727969B1 (de)
HU (1) HU215192B (de)
ZA (1) ZA9510447B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38520E1 (en) * 1996-02-28 2004-05-18 Aventis Pharma S.A. Erythromycin derivatives, method for preparing same, and use thereof as drugs
FR2745290B1 (fr) * 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
DE19652362A1 (de) 1996-12-17 1998-06-18 Thomson Brandt Gmbh Verfahren und Vorrichtung zur Kompensation der durch die Verarbeitung von Chrominanz-Signalen entstehenden Luminanzdefekte
US5955440A (en) * 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
US5972898A (en) * 1998-03-27 1999-10-26 Abbott Laboratories 3',3-N-bis-substituted macrolide LHRH antagonists
US6020521A (en) * 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) * 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
ES2243066T3 (es) 1998-09-22 2005-11-16 Pfizer Products Inc. Antibioticos de carbamato y carbazato cetolida.
FR2785612A1 (fr) * 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) * 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
ES2273964T3 (es) 1998-12-10 2007-05-16 Pfizer Products Inc. Antibioticos de carbamato y carbazato cetolida.
EA200100623A1 (ru) * 1999-01-27 2002-02-28 Пфайзер Продактс Инк. Кетолидные антибиотики
EA200100983A1 (ru) * 1999-05-24 2002-10-31 Пфайзер Продактс Инк. Производные 13-метилэритромицина
AU6183800A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
WO2001010878A1 (fr) * 1999-08-06 2001-02-15 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
AU6316400A (en) * 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
ID27331A (id) * 1999-09-29 2001-03-29 Pfizer Prod Inc Pembuatan antibiotik-antibiotik ketolida karbamat
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
EP1146051A3 (de) * 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A-Derivate
US20050014706A1 (en) * 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US20080287376A1 (en) * 2004-07-28 2008-11-20 Mohammad Salman Ketolide Derivatives as Antibacterial Agents
CA2591746A1 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Macrolides
US10130465B2 (en) 2016-02-23 2018-11-20 Abbott Cardiovascular Systems Inc. Bifurcated tubular graft for treating tricuspid regurgitation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
FR2692579B1 (fr) * 1992-06-19 1995-06-02 Roussel Uclaf Nouveaux dérivés de la picromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) * 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) * 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
HRP930014A2 (en) * 1993-01-08 1994-08-31 Pliva Pharm & Chem Works 9-deoxo-9a-aza-11-deoxy-9a-homoeritromycin a 9a, 11-cyclic carbamates
JPH07219312A (ja) * 1993-12-10 1995-08-18 Canon Inc 画像形成装置

Also Published As

Publication number Publication date
FR2727969B1 (fr) 1997-01-17
AU697876B2 (en) 1998-10-22
CA2164798A1 (fr) 1996-06-10
DE69505487D1 (de) 1998-11-26
US5786339A (en) 1998-07-28
ZA9510447B (en) 1996-12-09
CA2164798C (fr) 2007-03-20
HUT74075A (en) 1996-10-28
ATE172467T1 (de) 1998-11-15
JP4083824B2 (ja) 2008-04-30
CN1067077C (zh) 2001-06-13
AU4032495A (en) 1996-06-20
DE69505487T2 (de) 1999-05-12
JPH08231583A (ja) 1996-09-10
FR2727969A1 (fr) 1996-06-14
DK0716093T3 (da) 1999-06-28
CN1133291A (zh) 1996-10-16
ES2123934T3 (es) 1999-01-16
HU9503524D0 (en) 1996-02-28
KR960022553A (ko) 1996-07-18
KR100371473B1 (ko) 2003-07-22
HU215192B (hu) 1998-10-28
EP0716093A1 (de) 1996-06-12

Similar Documents

Publication Publication Date Title
EP0716093B1 (de) Erythromycin-Derivate, Verfahren zur Herstellung und Verwendung als Arzneimittel
EP0885234B1 (de) Erythramicin-derivate, ihre verfahren zur herstellung und ihre verwendung als arzneimittel
EP0606024B1 (de) Erythromycinderivate, ihr Verfahren zur Herstellung und ihre Verwendung als Arzneimitteln
EP1016669B1 (de) Erythromycin-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP0596802A1 (de) Erythromycinderivate, ihr Verfahren zur Herstellung und ihre Verwendung als Arzneimitteln
EP1026170B1 (de) Erythromycin-Derivate, ihr Verfahren zur Herstellung und ihre Verwendung als Arzneimittel
EP0974598B1 (de) Neue Erythromycin-Derivate, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
FR2692579A1 (fr) Nouveaux dérivés de la picromycine, leur procédé de préparation et leur application comme médicaments.
CA2118564C (fr) Derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
EP0946579B1 (de) Erythromycinderivate, verfahren zu ihrer herstellung, und ihrer verwendung als arzneimitteln
FR2754821A1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2751656A1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
EP0656364B1 (de) Erythromycinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
FR2691464A1 (fr) Nouveaux dérivés de la 1-oxa 6-azacyclopentadécane 13,15-dione, leur procédé de préparation et leur application comme médicaments.
EP1000952B1 (de) Neue 2-Halogen-Derivate von 5-O-Desosaminylerythronolid A, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP0946580B1 (de) Erythromycin-derivate, verfahren zu ihrer herstellung und ihrer verwendung
EP1098901B1 (de) 6-deoxy-erythromycin-derivate, ihrer herstellung, und ihrer verwendung als arzneimitteln
CA2247175C (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2792637A1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2780977A1 (fr) Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17P Request for examination filed

Effective date: 19961212

17Q First examination report despatched

Effective date: 19970206

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HOECHST MARION ROUSSEL

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

REF Corresponds to:

Ref document number: 172467

Country of ref document: AT

Date of ref document: 19981115

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69505487

Country of ref document: DE

Date of ref document: 19981126

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19981209

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: FRENCH

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2123934

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19981229

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Free format text: HOECHST MARION ROUSSEL TRANSFER- AVENTIS PHARMA S.A.

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

NLS Nl: assignments of ep-patents

Owner name: AVENTIS PHARMA S.A.

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Free format text: AVENTIS PHARMA, S.A. FR

Effective date: 20030110

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: AVENTIS PHARMA S.A.

Free format text: AVENTIS PHARMA S.A.#20, AVENUE RAYMOND ARON#92160 ANTONY (FR) -TRANSFER TO- AVENTIS PHARMA S.A.#20, AVENUE RAYMOND ARON#92160 ANTONY (FR)

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20141211

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20141212

Year of fee payment: 20

Ref country code: LU

Payment date: 20141211

Year of fee payment: 20

Ref country code: DE

Payment date: 20141202

Year of fee payment: 20

Ref country code: ES

Payment date: 20141111

Year of fee payment: 20

Ref country code: SE

Payment date: 20141211

Year of fee payment: 20

Ref country code: IE

Payment date: 20141209

Year of fee payment: 20

Ref country code: GR

Payment date: 20141112

Year of fee payment: 20

Ref country code: GB

Payment date: 20141203

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20141208

Year of fee payment: 20

Ref country code: PT

Payment date: 20141205

Year of fee payment: 20

Ref country code: NL

Payment date: 20141210

Year of fee payment: 20

Ref country code: AT

Payment date: 20141125

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20141210

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20141211

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69505487

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20151206

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20151205

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20151206

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20151205

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 172467

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151206

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20151205

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20151216

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 980402963

Country of ref document: GR

Effective date: 20151207

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20151207

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20151206